HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
- Southlake, TX, March 10, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has engaged Integrous Communications, a premier investor relations firm, to enhance communication channels with investors and the investment community. Under the expert guidance of Integrous Communications, HeartSciences will embark on a comprehensive investor relations program, benefiting from Integrous Communications' proven track record in collaborating with leading medical companies to develop and execute an effective investor relations program.
- 03/10/2025
|
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
- Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2025 ended October 31, 2024 and provided a business update.
- 12/16/2024
|
HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
- Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment APC 5734. This approval would allow outpatient settings to receive reimbursement for HeartSciences' MyoVista® wavECGTM algorithm and MyoVista® InsightsTM low ejection fraction algorithm, upon FDA clearance. The payment rate is expected to be $125.
- 11/13/2024
|
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
- Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that Company CEO Andrew Simpson has been invited to participate in the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC and hosted by M-Vest, from Tuesday October 15 to Thursday October 17, 2024.
- 10/14/2024
|
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
- Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update.
- 09/12/2024
|
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
- Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the close of a non-dilutive financing, with $1.9 million in net proceeds. The unsecured loan note has an 18-month maturity date and follows the recent 12-month extension of a $500,000 loan note to September 2025.
- 09/12/2024
|
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
- Southlake, TX, July 29, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the fiscal year 2024 ended April 30, 2024 and provided a business update.
- 07/29/2024
|
Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
- Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced an analysis published by the Innovation Value Institute (IVI) titled “Introduction of AI assisted Digital Health Technology to Improve Cardiovascular Pathway Efficiency” focused on the MyoVista® wavECG™'s potential to radically improve the cardiovascular pathway efficiency.
- 07/26/2024
|
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
- Southlake, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the MyoVista® wavECGTM has been selected by the Innovation Value Institute as a technology which can drive the radical transformation of healthcare and has been invited to demonstrate and discuss the MyoVista wavECG at the 4th Digital Health Symposium at the United Nations General Assembly to be held in New York, USA in September 2024.
- 07/25/2024
|
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
- Southlake, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that intellectual property (IP) exclusively licensed to HeartSciences has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for the detection of left ventricular (LV) and/or right ventricular (RV) dysfunction using deep learning, further strengthening the Company's AI-ECG IP portfolio. Heart failure (HF) is a growing worldwide public health issue affecting 64 million people annually1 and is associated with high mortality, lower quality of life and reduced physical capacity while placing substantial costs on the healthcare system.
- 07/11/2024
|
HeartSciences Regains Compliance with Nasdaq Listing Requirements
- Southlake, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that on June 3, 2024, the Company received formal notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC indicating that HeartSciences has regained compliance with bid price requirement as set forth in Listing Rule 5550(a)(2), and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements and the scheduled hearing has now been cancelled.
- 06/04/2024
|
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
- Southlake, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been granted Indian Patent Application 201817014481 by the Indian Patent Office (IPO). To date, HeartSciences has been granted nine US patents and 35 international patents for a total of 44 granted patents.
- 05/20/2024
|
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
- Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease
- 04/24/2024
|
HeartSciences to Present at the LD Micro Invitational XIV Conference
- Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York. Mr. Simpson will also be hosting one-on-one meetings through the conference.
- 04/02/2024
|
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
- Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended
- 03/26/2024
|
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
- Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.
- 03/14/2024
|
HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
- Data Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and ARIC HF score, the conventional standards of care for Stage B Heart Failure screening Data Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and ARIC HF score, the conventional standards of care for Stage B Heart Failure screening
- 03/12/2024
|
Why Is Heart Test Laboratories (HSCS) Stock Down 21% Today?
- Heart Test Laboratories (NASDAQ: HSCS ) stock is falling hard on Wednesday after the medical technology company announced a secondary offering for its shares. Heart Test Laboratories notes that this is a resale of 34,684,859 shares of HSCS stock by a few shareholders.
- 03/06/2024
|
HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
- Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Canadian Intellectual Property Office Application No. 3,000,369 has been granted by the Canadian Intellectual Property Office.
- 03/06/2024
|
HeartSciences Adds Key Advisor to its Scientific Advisory Board
- Southlake, TX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Partho P. Sengupta, MD, MBBS, FACC, to its Scientific Advisory Board.
- 02/26/2024
|
HeartSciences Expands its Scientific Advisory Board
- Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.
- 02/12/2024
|
HeartSciences Appoints New Scientific Advisory Board Member
- Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.
- 02/01/2024
|
HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
- Southlake, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today the results of the Company's 2024 Annual Meeting of Shareholders (the “Annual Meeting”) as well as an adjournment of the Annual Meeting as outlined below.
- 01/18/2024
|
HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting
- Southlake, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), would like to remind its shareholders to vote ahead of its upcoming 2023 Annual Meeting of Stockholders (“Annual Meeting”) on Wednesday, January 17, 2024 at 9:00 a.m. Eastern (8:00 a.m. Central) Time. All shareholders on record of our outstanding shares of common stock and preferred stock at the close of business on November 20, 2023, are entitled to participate and vote at the Annual Meeting.
- 01/03/2024
|
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
- Southlake, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.
- 12/14/2023
|
HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
- Southlake, TX, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has received confirmation from the FDA to change the clearance pathway for its MyoVista® wavECG™ device and associated AI-ECG algorithm to a more standard 510(k) submission from the more complex De Novo process.
- 12/05/2023
|
Penny Stocks To Buy? 5 To Watch Right Now
- Penny stocks refer to shares of small or micro-cap companies that trade for less than $5 per share. What cheap stocks lack in size and stability, they can potentially make up for in rapid price changes and explosive short-term gains.
- 11/22/2023
|
Why Is Heart Test Laboratories (HSCS) Stock Up 43% Today?
- Heart Test Laboratories (NASDAQ: HSCS ) stock is rising higher on Wednesday without any clear news from the maker of cardiovascular diagnostic devices. There have been no new press releases or filings with the Securities and Exchange Commission that explain why HSCS stock is rising higher today.
- 11/15/2023
|
HeartSciences' MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
- Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd (“Cardiact”) to be used in its heart screening program of members of the Association of Garda Sergeants and Inspectors (“AGSI”). In addition to the purchase of a MyoVista® device, Cardiact has placed an initial supplies order covering 2,400 patient tests.
- 11/13/2023
|
Why Is Heart Test Laboratories (HSCS) Stock Up 298% Today?
- Heart Test Laboratories (NASDAQ: HSCS ) stock is taking off on Wednesday despite a lack of news concerning the medical technology company. Investors will note that Heart Test Laboratories hasn't put out any new press releases or filings with the Securities and Exchange Commission (SEC) that explain today's rally.
- 11/08/2023
|
Why Is Heart Test Laboratories (HSCS) Stock Moving Today?
- Heart Test Laboratories (NASDAQ: HSCS ) stock is on the move Thursday after announcing an agreement with the Icahn School of Medicine at Mount Sinai. This new agreement has Heart Test Laboratories' HeartSciences working with Icahn Mount Sinai to commercialize electrocardiographic artificial intelligence ( AI ) algorithms and assets.
- 09/21/2023
|
HeartSciences Reports First Quarter Fiscal 2024 Financial Results
- Southlake, TX, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today provided a business update and reported financial results for the first quarter fiscal 2024 ended July 31, 2023.
- 09/14/2023
|
HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase
- Southlake, TX, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 11:30 am ET.
- 09/12/2023
|
HeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023
- Southlake, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today announces that CEO Andrew Simpson will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023.
- 04/17/2023
|
3 Tips for Using Technical Indicators to Find Penny Stocks to Buy
- Can these technical indicators help you make money with penny stocks? The post 3 Tips for Using Technical Indicators to Find Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/31/2023
|
HeartSciences to Present at MicroCap Rodeo's Windy City Roundup Conference on October 12th
- SOUTHLAKE, TX / ACCESSWIRE / October 6, 2022 / Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS; HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG's clinical usefulness by detecting cardiac dysfunction, today announced that Andrew Simpson, Chairman and Chief Executive Officer of HeartSciences, has been invited to present at the 2022 MicroCap Rodeo Windy City Roundup Conference, which is being held on October 12 - 13, 2022 in Chicago, Illinois. Mr. Simpson is scheduled to present on Wednesday, October 12th at 1:30 p.m.
- 10/06/2022
|
